Abstract

You have accessJournal of UrologyImaging/Radiology: Uroradiology I1 Apr 2018MP14-02 ROLE OF [18F] FLUORODEOXYGLUCOSE-PET IN DIFFERENTIATING PAPILLARY RENAL CELL CARCINOMA FROM CLEAR CELL RENAL CELL CARCINOMA AND ONCOCYTOMA Moozhan Nikpanah, Mark A. Ahlman, A. Cahid Civelek, S. Mojdeh Mirmomen, Xiaobai Li, Anna K. Paschall, Ramaprasad Srinivasan, Faraz Farhadi, W. Marston Linehan, and Ashkan A. Malayeri Moozhan NikpanahMoozhan Nikpanah More articles by this author , Mark A. AhlmanMark A. Ahlman More articles by this author , A. Cahid CivelekA. Cahid Civelek More articles by this author , S. Mojdeh MirmomenS. Mojdeh Mirmomen More articles by this author , Xiaobai LiXiaobai Li More articles by this author , Anna K. PaschallAnna K. Paschall More articles by this author , Ramaprasad SrinivasanRamaprasad Srinivasan More articles by this author , Faraz FarhadiFaraz Farhadi More articles by this author , W. Marston LinehanW. Marston Linehan More articles by this author , and Ashkan A. MalayeriAshkan A. Malayeri More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.495AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES We assessed differences in [18F] fluorodeoxyglucose (FDG) PET-derived standardized uptake value (SUV) of renal neoplasms, including papillary renal cell carcinoma (pRCC) type 1 and 2, clear cell renal cell carcinoma (ccRCC) and oncocytoma. METHODS In this retrospective study, 100 pathology proven renal lesions (25 pRCC type 1, 8 pRCC type 2, 57 ccRCC, 10 oncocytoma) that met our inclusion criteria (size ≥1cm, timeframe between the preoperative FDG PET/CT performed and surgery ≤18 months) were selected from 35 patients. Renal lesions with distant metastasis were identified. Two nuclear medicine specialists, blinded to clinical information, independently reviewed FDG-PET/CT images. With care to avoid urinary FDG activity, lesional SUV mean was determined and target to background ratio respective to liver (TBRLiver) was calculated. Intrarater reliability score was calculated by using unweighted k statistics to measure agreement between the readers. Values were averaged to a single measurement for each lesion. Linear mixed model was used to compare TBRLiver values among four categories of neoplasm. The model accounted for within-patient correlation and metastatic or non-metastatic designation of the lesions. RESULTS The 100 renal lesions were selected from 35 patients (24 male and 11 female, mean age: 54). Metastatic lesions included 9 pRCC type 1, 4 pRCC type 2, and 11 ccRCC. Intrarater reliability test resulted in a mean k score of 0.86. Median TBRLiver value (interquartile range) was 1.23 (0.53, 5.04) for pRCC type 1, 3.78 (0.49, 8.46) for pRCC type 2, 0.94 (0.41,2.21) for ccRCC, and 0.99 (0.63,1.41) for oncocytoma. The mixed model showed a significant difference in TBRLiver value among four categories (p=0.0003). Pairwise comparison showed significant difference in TBRLiver value between ccRCC and pRCC type 2 (p<0.0001), pRCC type 1 and pRCC type 2 (p=0.01), and oncocytoma and pRCC type 2 (p=0.025). CONCLUSIONS Papillary type 2 of renal cell carcinoma has higher FDG activity than clear cell RCC, papillary type 1 RCC, and oncocytoma. These findings are important to help determine if an imaging biomarker such as FDG is useful to study the genetic-metabolic linkages and clinical applicability in renal neoplasms. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e179-e180 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Moozhan Nikpanah More articles by this author Mark A. Ahlman More articles by this author A. Cahid Civelek More articles by this author S. Mojdeh Mirmomen More articles by this author Xiaobai Li More articles by this author Anna K. Paschall More articles by this author Ramaprasad Srinivasan More articles by this author Faraz Farhadi More articles by this author W. Marston Linehan More articles by this author Ashkan A. Malayeri More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.